MayMag Biologics Announces Industrial-Scale FDA 506(e) Outsourcing Capabilities to Secure US Biologics Supply Chain for Healthcare Distributors
Texas-based cGMP pharmaceutical manufacturer shifts paradigm from retail 503B compounding to large-scale, commercial production of FDA short-listed generic drugs and biosimilar biologics.
GARLAND, TX — MayMag Biologics (formerly operating as Zeptide Pharma and Tirzepatide Pharma), a premier U.S.-based cGMP pharmaceutical manufacturer, today announced its expanded industrial capacity as a premier FDA-registered 506(e) outsourcing manufacturer.
Unlike traditional retail 503B compounding facilities that focus on small-batch hospital or clinical office stock, MayMag Biologics operates strictly at an industrial 506(e) scale.
Reinforcing the U.S. Drug Supply Chain
National healthcare distributors face persistent supply chain fragility across key therapeutic categories. MayMag Biologics addresses these vulnerabilities by delivering commercial-scale supply redundancy across critical short-listed drugs, including:
GLP-1 Biologics & Diabetes Care: Large-scale formulation and batch filling of cGMP GLP-1 receptor agonists and insulin analogs.
Auto-Injector & Emergency Delivery: In-house 510(k) auto-injector device integration, including emergency epinephrine auto-injectors and rheumatoid arthritis delivery systems.
Ophthalmic & Inhalation Therapeutics: High-purity sterile glaucoma treatments and specialized inhalation formulations.
Essential Multi-Dose Diluents: High-volume commercial manufacturing of Bacteriostatic Water for Injection (BWFI) with 0.9% benzyl alcohol preservatives.
Quality Assurance & Device Continuity
Operating out of state-of-the-art facilities in Texas, MayMag Biologics maintains strict adherence to cGMP, ISO 13485, and USP <797>/<800> quality control frameworks.
"Healthcare distributors need more than localized compounders when critical drugs enter shortage status—they need reliable, commercial-scale manufacturing partners who understand batch stability, auto-device integration, and long-term supply redundancy," said a spokesperson for MayMag Biologics.
"As an industrial 506(e) manufacturer, our sole focus is delivering bulk biosimilars and shortage-mitigating generics directly into the distribution channels that power American healthcare."
MayMag Biologics invites regional and national pharmaceutical distributors, hospital group purchasing organizations (GPOs), and contract development partners to validate its FDA credentials and explore contract manufacturing capabilities.
About MayMag Biologics
MayMag Biologics is an FDA-registered 506(e) industrial pharmaceutical manufacturer headquartered in Texas.
Media & Distribution Inquiries:
MayMag Biologics Commercial CDMO Division
Email: cdmo@tirzepatidepharm.com
Website:

Comments
Post a Comment